474510-57-1 Purity
95%
If you have any other questions or need other size, please get a quote.
Specification
α-Zingiberene has been identified as a selective histone deacetylase 1 (HDAC1) inhibitor with potential therapeutic applications in trauma-induced neuropathic pain. Unlike traditional zinc-binding HDAC inhibitors, α-zingiberene operates through a non-zinc-dependent mechanism, enhancing selectivity and reducing off-target effects. In vitro studies demonstrated its potent inhibitory activity on HDAC1, with an IC50 of 2.3 ± 0.1 µM, while in vivo administration effectively alleviated neuropathic pain symptoms, including thermal hyperalgesia and mechanical allodynia. Mechanistically, α-zingiberene downregulates HDAC1 expression in spinal cord microglia, thereby modulating neuroinflammatory pathways associated with peripheral neuropathy. Its non-zinc-binding inhibition strategy offers a promising alternative to conventional HDAC inhibitors, improving safety and therapeutic efficacy in neurodegenerative and pain-related disorders.